(Q33889576)

29 July 2017

Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis (English)

1 reference

multidrug-resistant tuberculosis

29 July 2017

0 references

multiple drug resistance

1 reference

1 reference

1 reference

1 reference

Tina Papastavros

1

1 reference

29 July 2017

Lisa R Dolovich

2

1 reference

29 July 2017

Anne Holbrook

3

1 reference

29 July 2017

Lori Whitehead

4

1 reference

29 July 2017

Mark Loeb

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Canadian Medical Association Journal

29 July 2017

1 reference

29 July 2017

167

1 reference

29 July 2017

131-136

1 reference

29 July 2017

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

29 July 2017

1 reference

Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Fluoroquinolone toxicity profiles: a review focusing on newer agents

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

A method for estimating the probability of adverse drug reactions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

The role of pyrazinamide in tuberculosis chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Levofloxacin, a second-generation fluoroquinolone.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=117089

Hepatotoxicity after a short course of low-dose pyrazinamide

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12160118

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12160118

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12160118

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

PMCID

117089

1 reference

29 July 2017

1 reference